EMIS +
Cellular Lipid Matrix
Cellular Lipid Matrix
Couldn't load pickup availability
Product Overview
The EMIS+ Cellular Lipid Matrix is a laboratory-based diagnostic assessment that provides a granular evaluation of lipid metabolism and cardiovascular risk markers. Unlike conventional lipid panels that report only total cholesterol, LDL-C, HDL-C, and triglycerides, this advanced panel quantifies LDL particle number (LDL-P), LDL peak particle size, small dense LDL concentration, oxidised LDL (ox-LDL), lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), and key inflammatory lipid ratios. These markers are recognised by the National Lipid Association (NLA) and the European Atherosclerosis Society (EAS) as superior predictors of residual cardiovascular risk.
Available exclusively through EMIS+ at emis.asia in Singapore, the Cellular Lipid Matrix is designed for healthcare professionals, preventive medicine practitioners, and individuals who require precision cardiovascular diagnostics. The test is processed through accredited laboratory facilities that conform to ISO 15189 medical laboratory standards, ensuring analytical accuracy and clinical reliability for each biomarker measured.
Specifications
| Provider | EMIS+ (Essential Medical International Supplies Pte Ltd), Singapore |
| Test Type | Advanced Lipid Panel & Cardiovascular Risk Assessment |
| Key Biomarkers | LDL-P (particle number), LDL peak size, sdLDL, ox-LDL, Lp(a), ApoB, Total Cholesterol, HDL-C, LDL-C, Triglycerides, inflammatory lipid ratios |
| Sample Requirement | Fasting venous blood draw (10–12 hour fast recommended) |
| Turnaround Time | 5–7 working days from sample receipt |
| Laboratory Standards | ISO 15189 accredited medical laboratory; ISO 17025 calibration compliance |
| Regulatory Framework | Singapore HSA-regulated diagnostic service; laboratory quality management per ISO 15189:2022 |
| Report Format | Comprehensive PDF report with reference ranges, risk stratification, and clinical interpretation notes |
| Price | SGD 226.00 |
Clinical Indications
- Residual cardiovascular risk assessment in patients with normal LDL-C but elevated ApoB or LDL-P, as recommended by the National Lipid Association (NLA) guidelines
- Familial hypercholesterolaemia screening and risk stratification where standard lipid panels are insufficient for clinical decision-making
- Metabolic syndrome evaluation including assessment of atherogenic dyslipidaemia characterised by elevated triglycerides, low HDL-C, and predominance of small dense LDL particles
- Monitoring therapeutic efficacy of statin therapy, PCSK9 inhibitors, or lifestyle interventions by tracking LDL particle number reduction alongside LDL-C levels
- Preventive cardiovascular health screening for individuals with a family history of premature coronary artery disease or elevated Lp(a) levels, per European Atherosclerosis Society (EAS) consensus recommendations
- Cellular membrane health assessment for patients presenting with chronic fatigue or inflammatory conditions where lipid peroxidation markers may inform clinical management
Frequently Asked Questions
How does the Cellular Lipid Matrix differ from a standard lipid panel available at Singapore polyclinics?
A standard lipid panel measures four markers: total cholesterol, LDL-C, HDL-C, and triglycerides. The Cellular Lipid Matrix extends this to include LDL particle number and size distribution, oxidised LDL, lipoprotein(a), and apolipoprotein B. Research published in the Journal of Clinical Lipidology demonstrates that LDL-P and ApoB are superior predictors of atherosclerotic cardiovascular disease events compared with LDL-C alone, particularly in patients with discordant LDL-C and LDL-P values.
Is fasting required before the blood draw for this test?
Yes. A 10–12 hour overnight fast is recommended to ensure accurate measurement of triglycerides and lipoprotein subfractions. Water consumption is permitted during the fasting period. Clinicians should advise patients to maintain their usual medication schedule unless specifically instructed otherwise.
Who should consider ordering the Cellular Lipid Matrix?
This test is clinically indicated for individuals with a family history of premature cardiovascular disease, patients with metabolic syndrome or insulin resistance, those on lipid-lowering therapy requiring detailed treatment monitoring, and anyone whose standard lipid panel results appear normal but who has other cardiovascular risk factors. The European Atherosclerosis Society recommends Lp(a) measurement at least once in every adult's lifetime for cardiovascular risk assessment.
Are the results reviewed by a medical professional?
The laboratory report includes reference ranges and interpretive notes. EMIS+ recommends that all results be reviewed with a qualified healthcare provider — such as a cardiologist, endocrinologist, or preventive medicine physician — who can contextualise the findings within the patient's complete clinical history and guide appropriate therapeutic interventions.
Can this test be used for monitoring statin or PCSK9 inhibitor therapy?
Yes. Tracking LDL-P and ApoB levels provides a more precise measure of therapeutic response than LDL-C alone. The NLA recommends ApoB or LDL-P as secondary treatment targets, particularly in patients who achieve LDL-C goals but retain elevated particle counts, a condition known as LDL-C/LDL-P discordance that is associated with residual cardiovascular risk.